Which company manufactures Margetuximab/Meganex?

Margetuximab is an innovative humanized monoclonal antibody targeting the HER2 receptor, developed and produced by MacroGenics, Inc. Manulife Pharmaceuticals, headquartered in the United States, is a biopharmaceutical company focusing on antibody drugs and immuno-oncology treatment. It has rich experience and leading technology in antibody drug design and clinical development. The company is committed to developing new monoclonal antibodies, bispecific antibodies and antibody conjugate drugs, especially in the field of cancer immunotherapy. It has significant advantages. Margituximab is one of the key projects in its innovative drug pipeline.

The development of margetuximab originated from the need to optimize the treatment of patients with HER2-positive breast cancer. Although traditional HER2 antibodies have played an important role in improving patient prognosis, some patients may still develop drug resistance or relapse after receiving Herceptin (Trastuzumab) treatment. Manulife Pharma optimizes the Fc segment of antibodies to enable immune effector cells to recognize and attack HER2-positive tumor cells more efficiently, thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC) and improving therapeutic potential.

Globally, Manulife Pharma has collaborated with a number of medical institutions and clinical research centers to conduct extensive multi-center clinical trials to verify the safety and efficacy of margetuximab in patients with advanced or recurrent HER2-positive breast cancer. At the same time, the company is also actively promoting the registration and listing of margetuximab in different markets, including European, American and Asian markets, to provide more patients with innovative treatment options. In China, Manulife Pharmaceuticals has successfully promoted the launch of margituximab through collaboration with local partners and registration agencies, allowing domestic patients with HER2-positive breast cancer to obtain this innovative drug. In addition to the treatment of HER2-positive breast cancer, Manulife Pharmaceuticals is also exploring the potential of combination therapy with margituximab, immune checkpoint inhibitors, targeted small molecule drugs, etc., striving to provide more treatment opportunities for drug-resistant or relapsed patients.

Reference materials:https://www.margenza.com/